相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antiangiogenic and Radiation Therapy Early Effects on In Vivo Computed Tomography Perfusion Parameters in Human Colon Cancer Xenografts in Mice
Ying Ren et al.
INVESTIGATIVE RADIOLOGY (2012)
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
Sarah J. Conley et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Targeting MET in cancer: rationale and progress
Ermanno Gherardi et al.
NATURE REVIEWS CANCER (2012)
Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects
Puja Sapra et al.
ANGIOGENESIS (2011)
Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response
Adam C. Yopp et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma
Ioanna Papandreou et al.
BLOOD (2011)
Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas
D. Tseng et al.
BRITISH JOURNAL OF CANCER (2011)
EMT A new vision of hypoxia promoting cancer progression
Jian Jiang et al.
CANCER BIOLOGY & THERAPY (2011)
Vascular normalization: a real benefit?
Domenico Ribatti
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of Rebound Revascularization as Mode of Escape
Emmanuelle di Tomaso et al.
CANCER RESEARCH (2011)
Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors
Yuanmei Lou et al.
CANCER RESEARCH (2011)
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
Weon-Kyoo You et al.
CANCER RESEARCH (2011)
Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2011)
Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells
Louisa von Baumgarten et al.
CLINICAL CANCER RESEARCH (2011)
CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
Dan G. Duda et al.
CLINICAL CANCER RESEARCH (2011)
Potential of CXCR4 antagonists for the treatment of metastatic lung cancer
Jan A. Burger et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Anticancer drugs that target metabolism: is dichloroacetate the new paradigm?
Ioanna Papandreou et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Effects of the antiangiogenic drug bevacizumab on tumor perfusion and drug delivery of 11C-labeled docetaxel in patients with non-small cell lung cancer (NSCLC): Implications for scheduling of antiangiogenic agents.
E. F. Smit et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
Richard H. de Boer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Adam M. Brufsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Ronald B. Natale et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular Imaging of Hypoxia
Satish K. Chitneni et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
John M. L. Ebos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
Katrien De Bock et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Peter Carmeliet et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES
Shom Goel et al.
PHYSIOLOGICAL REVIEWS (2011)
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
Olivier Keunen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality
Denise A. Chan et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Targeting hypoxia in cancer therapy
William R. Wilson et al.
NATURE REVIEWS CANCER (2011)
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
M. Reck et al.
ANNALS OF ONCOLOGY (2010)
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
Carlos H. Barrios et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
N. Murukesh et al.
BRITISH JOURNAL OF CANCER (2010)
CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression
Xueqing Sun et al.
CANCER AND METASTASIS REVIEWS (2010)
Imaging the Unfolded Protein Response in Primary Tumors Reveals Microenvironments with Metabolic Variations that Predict Tumor Growth
Michael T. Spiotto et al.
CANCER RESEARCH (2010)
HIF-2α Enhances β-Catenin/TCF-Driven Transcription by Interacting with β-Catenin
Hyunsung Choi et al.
CANCER RESEARCH (2010)
Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor, Inhibits HIF-1α Expression in an AhR-Independent Fashion
Erika Terzuoli et al.
CANCER RESEARCH (2010)
Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors
Kevin O. Hicks et al.
CLINICAL CANCER RESEARCH (2010)
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Beverly A. Teicher et al.
CLINICAL CANCER RESEARCH (2010)
Targeting Hypoxic Cells through the DNA Damage Response
Monica Olcina et al.
CLINICAL CANCER RESEARCH (2010)
HIF-1: upstream and downstream of cancer metabolism
Gregg L. Semenza
CURRENT OPINION IN GENETICS & DEVELOPMENT (2010)
Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer
Johanna Chiche et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice
Mitomu Kioi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5
Kasper M. A. Rouschop et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II-study of PRO95780 plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL)
S. Wittebol et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
David W. Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Hypoxia-Inducible Factors and the Response to Hypoxic Stress
Amar J. Majmundar et al.
MOLECULAR CELL (2010)
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
Roy S. Herbst et al.
LANCET ONCOLOGY (2010)
Pazopanib
Ronald M. Bukowski et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
G. L. Semenza
ONCOGENE (2010)
Regulation of autophagy by ATF4 in response to severe hypoxia
T. Rzymski et al.
ONCOGENE (2010)
Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the Premetastatic Niche
Janine T. Erler et al.
CANCER CELL (2009)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads
Annamaria Rapisarda et al.
CELL CYCLE (2009)
Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis
Erwan Pencreach et al.
CLINICAL CANCER RESEARCH (2009)
Regulation of Autophagy Through Multiple Independent Hypoxic Signaling Pathways
Kasper M. A. Rouschop et al.
CURRENT MOLECULAR MEDICINE (2009)
Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
Annamaria Rapisarda et al.
DRUG RESISTANCE UPDATES (2009)
Molecular imaging of hypoxia with radiolabelled agents
Gilles Mees et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Glucose deprivation-induced metabolic oxidative stress and cancer therapy
Andrean L. Simons et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2009)
Hypoxia-inducible factors in stem cells and cancer
Jolly Mazumdar et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Development of HIF-1 inhibitors for cancer therapy
Barbara Onnis et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival
Ashwatha Narayana et al.
JOURNAL OF NEUROSURGERY (2009)
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
Annamaria Rapisarda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis
Tibor Schomber et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Avastin-Tarceva combination fails in lung cancer
Dan Jones
NATURE BIOTECHNOLOGY (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Human cancers converge at the HIF-2α oncogenic axis
Aleksandra Franovic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
被撤回的出版物: Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells (Retracted article. See vol. 119, 2022)
KangAe Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition
Duyen T. Dang et al.
CANCER RESEARCH (2008)
Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells
James W. Evans et al.
CANCER RESEARCH (2008)
Preferential Cytotoxicity of Bortezomib toward Hypoxic Tumor Cells via Overactivation of Endoplasmic Reticulum Stress Pathways
Diane R. Fels et al.
CANCER RESEARCH (2008)
Glycolytic enzyme inhibitors in cancer treatment
Roberto Scatena et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1 alpha
Mei Y. Koh et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib
Timothy P. Padera et al.
MOLECULAR CANCER THERAPEUTICS (2008)
A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
Lee M. Greenberger et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Christian Fischer et al.
NATURE REVIEWS CANCER (2008)
Hypoxia signalling through mTOR and the unfolded protein response in cancer
Bradly G. Wouters et al.
NATURE REVIEWS CANCER (2008)
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Nicholas C. Denko
NATURE REVIEWS CANCER (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Hypoxia and metabolism - Opinion - The interplay between MYC and HIF in cancer
Chi V. Dang et al.
NATURE REVIEWS CANCER (2008)
DNA repair pathways as targets for cancer therapy
Thomas Helleday et al.
NATURE REVIEWS CANCER (2008)
Hypoxia, DNA repair and genetic instability
Robert G. Bristow et al.
NATURE REVIEWS CANCER (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Oxygen sensing and the DNA-damage response
Ester M. Hammond et al.
CURRENT OPINION IN CELL BIOLOGY (2007)
Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor
Jens Koditz et al.
BLOOD (2007)
Anti-PIGF inhibits growth of VEGF(R)-Inhibitor-Resistant tumors without affecting healthy vessels
Christian Fischer et al.
CELL (2007)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography:: A pilot study
Wei Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Farbod Shojaei et al.
NATURE BIOTECHNOLOGY (2007)
Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231
Shannon M. Gallagher et al.
CANCER RESEARCH (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Is angiogenesis an organizing principle in biology and medicine?
Judah Folkman
JOURNAL OF PEDIATRIC SURGERY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
Yuval Shaked et al.
SCIENCE (2006)
Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression
Girma M. Woldemichael et al.
JOURNAL OF BIOMOLECULAR SCREENING (2006)
VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization
Bin Li et al.
FASEB JOURNAL (2006)
Regulation of angiogenesis by hypoxia-inducible factor 1
Kiichi Hirota et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Antianglogenic potential of the mammalian target of rapamycin inhibitor temsirolimus
Donatella Del Bufalo et al.
CANCER RESEARCH (2006)
Hypoxia signalling in cancer and approaches to enforce tumour regression
Jacques Pouyssegur et al.
NATURE (2006)
CCl-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1α/VEGF signaling
Xiaolin Wan et al.
NEOPLASIA (2006)
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia
M Franco et al.
CANCER RESEARCH (2006)
HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia
JW Kim et al.
CELL METABOLISM (2006)
Inhibiting hypoxia-inducible factor 1 for cancer therapy
Giovanni Melillo
MOLECULAR CANCER RESEARCH (2006)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
RD Guzy et al.
CELL METABOLISM (2005)
Hypoxia-mediated down-regulation of bid and bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance
JT Erler et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications
A Rapisarda et al.
CANCER RESEARCH (2004)
Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation
EM Hammond et al.
CANCER RESEARCH (2004)
XBP1 is essential for survival under hypoxic conditions and is required for tumor growth
L Romero-Ramirez et al.
CANCER RESEARCH (2004)
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
DJ Ceradini et al.
NATURE MEDICINE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Schedule-dependent inhibition of hypoxia-inducible factor-1α protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts
A Rapisarda et al.
CANCER RESEARCH (2004)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2α
C Koumenis et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Clinical translation of angiogenesis inhibitors
R Kerbel et al.
NATURE REVIEWS CANCER (2002)
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
JS Isaacs et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Hypoxia - A key regulatory factor in tumour growth
AL Harris
NATURE REVIEWS CANCER (2002)
分享论文
